Richard Wu
Medical Oncology · Columbus, OHNPI 1104260744
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,838 of the $3,063 with a category attached, or 60.0%. 15 manufacturers reported payments, led by AstraZeneca at 29.7% of the total. Reporting peaked in 2019 at $1,701 and has fallen 93.2% since, to $116 in 2025. That places this record below the midpoint for medical oncology clinicians in OH, where the typical reported total is $2,659.
Across 24 payments — averaging $127.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$911
- Sanofi$450
- Genentech USA, Inc.$268
- E.r. Squibb & Sons, L.L.C.$267
- Clinigen, Inc.$157
- Array Biopharma Inc$124
- plus $887 from 9 others
Across 284 payments — averaging $2003.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$569K
What the payments were for
- Consulting fees$52517%
- Speaking & faculty fees$60020%
- Food & beverage$1,83860%
- Education$1003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 4 | $911 |
| Sanofi | 3 | $450 |
| Genentech USA, Inc. | 2 | $268 |
| E.r. Squibb & Sons, L.L.C. | 3 | $267 |
| Clinigen, Inc. | 1 | $157 |
| Array Biopharma Inc | 2 | $124 |
| Puma Biotechnology, Inc. | 1 | $122 |
| Amgen | 1 | $107 |
| Johnson & Johnson | 1 | $102 |
| Astellas Pharma US Inc | 1 | $102 |
| Regeneron | 1 | $102 |
| Incyte Corporation | 1 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $98 |
| Pfizer | 1 | $81 |
| Foundation Medicine, Inc. | 1 | $73 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,063 in reported general payments places this provider in the 50th percentile of 157 medical oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OdomzoSonidegib Phosphate | 11 | $74,820 |
| Levothyroxine Sodium | 14 | $100 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Columbus
- David CarboneColumbus$438K
- Christian RolfoColumbus$227K
- Timothy MooreColumbus$213K
- Maryam LustbergColumbus$176K
- Timothy BurnsColumbus$64K
- Kai HeColumbus$49K
- Gregory OttersonColumbus$49K
- Sagar SardesaiColumbus$45K
- Asrar AlahmadiColumbus$36K
- John HaysColumbus$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.